Review



nifuroxazide  (Valiant Co Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Valiant Co Ltd nifuroxazide
    Nifuroxazide, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0215583310/Nifuroxazide/pmc04182171-112-35-40
    Average 90 stars, based on 5 article reviews
    nifuroxazide - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Synthesized:

    Article Title: NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways
    Article Snippet: .. KIN193 (1 μ m ) and GDC-0032 (1 μ m ) from Haoyuan Chemexpress (Shanghai, China); NVP-BYL719 (1 μ m ), GS-1101 (1 μ m ) and AZD-1480 (1 μ m ) were synthesized by Chemitek (Indianapolis, IN, USA) were from and nifuroxazide (10 μ m ) were from MP Biomedicals (Santa Ana, CA, USA). .. Cells were plated in 96-well plates and treated with different concentrations of GDC-0032 (1, 0.5 and 0.25 μ m ) and nifuroxazide (10, 5, 2 μ m ) either alone or in combination pairings and MTS assay was performed after 48 h. The results were put into CompuSyn software ( http://www.combosyn.com ) and combination indeces were calculated as using the Chou–Talalay method [ ].

    other:

    Article Title: Action of nitroheterocyclic drugs against Clostridium difficile
    Article Snippet: Antibiotics were obtained from the following sources: metronidazole, vancomycin, fusidic acid, rifaximin and nitazoxanide were from Sigma-Aldrich (St Louis, MO); ornidazole was from Alfa Aesar (Ward Hill, MA); nitrofurazone was from TCI America (Portland, OR); nifuroxazide and furazolidone were from MP Biomedicals (Santa Ana, CA); and nitrofurantoin was from Acros Organics (Fair Lawn, NJ).

    Article Title: Signal transducer and activator of transcription 3‐mediated CD133 up‐regulation contributes to promotion of hepatocellular carcinoma
    Article Snippet: Sorafenib, (4-[4-[[4-chloro-3-(trifluoromethyl)phenyl] carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide) and nifuroxazide (4-hydroxy-N[(5-nitro-2-furanyl)methylene]hydrazide) were obtained from Bayer Pharmaceutical (Muellerstrasse, Berlin, Germany) and MP Biomedicals (Santa Ana, CA), respectively.

    Article Title: Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia
    Article Snippet: Nifuroxazide was purchased from MP Biomedicals.

    Article Title: Drug-enhanced carbon monoxide production from heme by cytochrome P450 reductase
    Article Snippet: The nitro-furanyl-methylene-hydrazides, nifuroxazide (MP Biomedicals, Solon, OH, USA) and furazolidone (Sigma-Aldrich), as well as a number of OT compounds increased CO generation by approximately 3- to 4-fold ( ).



    Similar Products

    nifuroxazide  (Valiant Co Ltd)
    90
    Valiant Co Ltd nifuroxazide
    Effects of ivermectin and <t>nifuroxazide</t> on mitochondrial ATP levels under hypoxia in primary cardiomyocytes. (a) A schematic of mito-ATeam knock-in animals for the isolation of primary cardiomyocytes. (b) Representative images of mito-ATeam in primary cardiomyocytes isolated from mito-ATeam knock-in neonatal hearts stained for mitochondria (red) and nuclei (blue); mito-ATeam is in green. Scale bar, 10 μm. (c) Quantified FRET ratios of mito-ATeam knock-in primary cardiomyocytes pre-treated with vehicle (V), ivermectin (2 or 5 μM; I2 or I5), or nifuroxazide (10 μM, N10) for 24 h followed by hypoxia/reoxygenation. Data are presented as means ± SD ( n = 3 biologically independent samples).
    Nifuroxazide, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0215583310/Nifuroxazide/pmc05652136-28-0-4
    Average 90 stars, based on 1 article reviews
    nifuroxazide - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    chloro  (Valiant Co Ltd)
    90
    Valiant Co Ltd chloro
    Effects of ivermectin and <t>nifuroxazide</t> on mitochondrial ATP levels under hypoxia in primary cardiomyocytes. (a) A schematic of mito-ATeam knock-in animals for the isolation of primary cardiomyocytes. (b) Representative images of mito-ATeam in primary cardiomyocytes isolated from mito-ATeam knock-in neonatal hearts stained for mitochondria (red) and nuclei (blue); mito-ATeam is in green. Scale bar, 10 μm. (c) Quantified FRET ratios of mito-ATeam knock-in primary cardiomyocytes pre-treated with vehicle (V), ivermectin (2 or 5 μM; I2 or I5), or nifuroxazide (10 μM, N10) for 24 h followed by hypoxia/reoxygenation. Data are presented as means ± SD ( n = 3 biologically independent samples).
    Chloro, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0215583310/Nifuroxazide/pmc05049669__HEP___62___1160___s001-10-1-15
    Average 90 stars, based on 1 article reviews
    chloro - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Effects of ivermectin and nifuroxazide on mitochondrial ATP levels under hypoxia in primary cardiomyocytes. (a) A schematic of mito-ATeam knock-in animals for the isolation of primary cardiomyocytes. (b) Representative images of mito-ATeam in primary cardiomyocytes isolated from mito-ATeam knock-in neonatal hearts stained for mitochondria (red) and nuclei (blue); mito-ATeam is in green. Scale bar, 10 μm. (c) Quantified FRET ratios of mito-ATeam knock-in primary cardiomyocytes pre-treated with vehicle (V), ivermectin (2 or 5 μM; I2 or I5), or nifuroxazide (10 μM, N10) for 24 h followed by hypoxia/reoxygenation. Data are presented as means ± SD ( n = 3 biologically independent samples).

    Journal: EBioMedicine

    Article Title: Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia

    doi: 10.1016/j.ebiom.2017.09.022

    Figure Lengend Snippet: Effects of ivermectin and nifuroxazide on mitochondrial ATP levels under hypoxia in primary cardiomyocytes. (a) A schematic of mito-ATeam knock-in animals for the isolation of primary cardiomyocytes. (b) Representative images of mito-ATeam in primary cardiomyocytes isolated from mito-ATeam knock-in neonatal hearts stained for mitochondria (red) and nuclei (blue); mito-ATeam is in green. Scale bar, 10 μm. (c) Quantified FRET ratios of mito-ATeam knock-in primary cardiomyocytes pre-treated with vehicle (V), ivermectin (2 or 5 μM; I2 or I5), or nifuroxazide (10 μM, N10) for 24 h followed by hypoxia/reoxygenation. Data are presented as means ± SD ( n = 3 biologically independent samples).

    Article Snippet: Nifuroxazide was purchased from MP Biomedicals.

    Techniques: Knock-In, Isolation, Staining

    Identification of ivermectin and nifuroxazide as mitochondrial ATP modulators under hypoxia by phenotypic screens. (a) Assay workflow to identify small molecules that maintain mitochondrial ATP levels under hypoxia with cardiac anti-hypertrophic effects. (b) Stacked histogram of the primary screen. Thirty-four primary hits (orange) were identified by the hit criteria (vehicle average + 3 SD = 0.931) indicated by dashed line and other parameters. (c) Scatter plot of results of mito-ATeam assays (protection against hypoxia- or oligomycin A [OA]-mediated mitochondrial ATP decrease). Each data point represents the average of three independent experiments, normalized to initial values (OA) or negative and positive controls (hypoxia) (initial value was set to 1). Grey dashed lines indicate the thresholds (> 80% for x axis and < 0.9 for y axis). Blue dashed line indicates OA response in vehicle group. Twenty-six compounds shown in black were excluded based on the counter-assays (cell viability and mitochondrial membrane potential) (Fig. S2a). Out of eight selected compounds, ivermectin and nifuroxazide (shown in orange) exhibited protective effects on mitochondrial ATP under hypoxia, but not in response to OA, without activating caspase-3/7 (Fig. S2b). Source data are available online for this figure (Table S1). (d and e) Representative images of fluorescence resonance energy transfer (FRET) signal in mito-ATeam stable HL-1 cardiomyocytes treated with ivermectin (d, upper panel) or nifuroxazide (e, upper panel) for 24 h under hypoxia (1% O 2 ), followed by reoxygenation (21% O 2 ). Scale bars, 20 μm. Quantified FRET ratios of mito-ATeam in HL-1 cardiomyocytes treated with ivermectin (0, 1, 3, 10 μM, d, lower panel) or nifuroxazide (0, 1, 3, 10 μM, e, lower panel) under hypoxia/reoxygenation are shown. Data are presented as means ± SD ( n = 3 biologically independent samples).

    Journal: EBioMedicine

    Article Title: Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia

    doi: 10.1016/j.ebiom.2017.09.022

    Figure Lengend Snippet: Identification of ivermectin and nifuroxazide as mitochondrial ATP modulators under hypoxia by phenotypic screens. (a) Assay workflow to identify small molecules that maintain mitochondrial ATP levels under hypoxia with cardiac anti-hypertrophic effects. (b) Stacked histogram of the primary screen. Thirty-four primary hits (orange) were identified by the hit criteria (vehicle average + 3 SD = 0.931) indicated by dashed line and other parameters. (c) Scatter plot of results of mito-ATeam assays (protection against hypoxia- or oligomycin A [OA]-mediated mitochondrial ATP decrease). Each data point represents the average of three independent experiments, normalized to initial values (OA) or negative and positive controls (hypoxia) (initial value was set to 1). Grey dashed lines indicate the thresholds (> 80% for x axis and < 0.9 for y axis). Blue dashed line indicates OA response in vehicle group. Twenty-six compounds shown in black were excluded based on the counter-assays (cell viability and mitochondrial membrane potential) (Fig. S2a). Out of eight selected compounds, ivermectin and nifuroxazide (shown in orange) exhibited protective effects on mitochondrial ATP under hypoxia, but not in response to OA, without activating caspase-3/7 (Fig. S2b). Source data are available online for this figure (Table S1). (d and e) Representative images of fluorescence resonance energy transfer (FRET) signal in mito-ATeam stable HL-1 cardiomyocytes treated with ivermectin (d, upper panel) or nifuroxazide (e, upper panel) for 24 h under hypoxia (1% O 2 ), followed by reoxygenation (21% O 2 ). Scale bars, 20 μm. Quantified FRET ratios of mito-ATeam in HL-1 cardiomyocytes treated with ivermectin (0, 1, 3, 10 μM, d, lower panel) or nifuroxazide (0, 1, 3, 10 μM, e, lower panel) under hypoxia/reoxygenation are shown. Data are presented as means ± SD ( n = 3 biologically independent samples).

    Article Snippet: Nifuroxazide was purchased from MP Biomedicals.

    Techniques: Fluorescence, Förster Resonance Energy Transfer